May 26, 2016
AstraZeneca K.K. launched the non-small cell lung cancer (NSCLC) treatment Tagrisso (osimertinib) on May 25. Tagrisso is indicated for the treatment of unresectable or relapsed EGFR T790M mutation-positive NSCLC resistant to EGFR tyrosine kinase inhibitors. Its NHI prices are 12,482.50...read more